01—Abstract
Summary
Summary of the 8-K/A filed June 10, 2026. Cited figures are marked; the original filing is the authoritative source.
Biogen Inc. (BIIB) has filed an amendment to its previous 8-K filing dated May 14, 2026.
The company is clarifying that the previously disclosed acquisition of Apellis Pharmaceuticals, Inc. did not constitute a "significant" acquisition under Regulation S-X. Consequently, Biogen will not be filing the financial statements of Apellis or the pro forma financial information related to the merger as initially anticipated. This amendment is primarily an administrative update to correct the reporting requirements associated with the Apellis acquisition.
Investors should note that this filing does not alter the fundamental terms or completion of the acquisition itself, but rather clarifies the regulatory reporting obligations post-transaction. The original disclosures regarding the consummation of the merger remain unchanged.
02—Key points
Key Highlights
- Biogen Inc. amends prior 8-K filing regarding the acquisition of Apellis Pharmaceuticals.
- The Apellis acquisition is determined not to be a "significant" acquisition per Regulation S-X.
- Biogen will not file Apellis's financial statements (Item 9.01(a)).
- Biogen will not file pro forma financial information for the merger (Item 9.01(b)).
- This filing clarifies reporting obligations, not the transaction's completion.
- Original disclosures about the merger's consummation remain in effect.
03—Questions
Frequently Asked Questions
Why is Biogen filing an amendment to its 8-K regarding the Apellis acquisition?
Biogen is filing this amendment to clarify that the acquisition of Apellis Pharmaceuticals does not meet the criteria for a 'significant' acquisition under Regulation S-X. As a result, the company is not required to file the financial statements of Apellis or pro forma financial information related to the merger, which was initially indicated as a possibility in the original filing.
Does this mean the acquisition of Apellis is no longer happening or has changed?
No, this amendment does not affect the completion or terms of the Apellis acquisition. Biogen is confirming that the merger has been consummated as previously disclosed. The amendment only addresses the specific financial reporting requirements that are no longer applicable due to the acquisition's non-significant status.
What are the implications for investors of this clarification?
For investors, the primary implication is that they will not receive additional financial filings (Apellis's statements or pro forma data) related to the Apellis acquisition because it was deemed not significant enough to require them. This simplifies the information flow but does not change the strategic or financial impact of the acquisition itself.
04—Continue